Effects of the topically applied calcium-channel blocker flunarizine on intraocular pressure in clinically normal dogs

American Journal of Veterinary Research

Volumn 69, Issue 2, 2008, Pages 273-278

  Greller, Andrew L ^a   Hoffman, Allison R ^a   Liu, Chengcheng ^b   Ying, Gui Shuang ^b   Vudathala, Daljit K ^b   Acland, Gregory M ^c   Komáromy, András M ^b  

^a Eye Care For Animals   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; FLUNARIZINE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; FEMALE; INTRAOCULAR PRESSURE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; TONOMETRY; TREND STUDY;

ADMINISTRATION, TOPICAL; ANIMALS; CALCIUM CHANNEL BLOCKERS; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUNARIZINE; HEALTH; INTRAOCULAR PRESSURE; MALE; TIME FACTORS;

ANIMALIA; CANIS FAMILIARIS;

EID: 39549105137     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.2.273     Document Type: Article

References (43)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:253-254.
2. Gelatt KN, MacKay EO. Prevalence of the breed-related glaucomas in pure-bred dogs in North America. Vet Ophthalmol 2004;7:97-111.
3. Fechtner RD, Weinreb RN. Mechanisms of optic nerve damage in primary open angle glaucoma. Surv Ophthalmol 1994;39:23-42.
4. Flammer J, Orgül S. Optic nerve blood-flow abnormalities in glaucoma. Prog Retin Eye Res 1998;17:267-289.
5. Gelatt KN, Miyabayashi T, Gelatt-Nicholson KJ, et al. Progressive changes in ophthalmic blood velocities in Beagles with primary open angle glaucoma. Vet Ophthalmol 2003;6:77-84.
6. Brooks DE, Garcia GA, Dreyer EB, et al. Vitreous body glutamate concentration in dogs with glaucoma. Am J Vet Res 1997;58:864-867.
7. Schwartz M. Neurodegeneration and neuroprotection in glaucoma: development of a therapeutic neuroprotective vaccine - the Friedenwald lecture. Invest Ophthalmol Vis Sci 2003;44:1407-1411.
8. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363:1711-1720.
9. Netland PA, Chaturvedi N, Dreyer EB. Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am J Ophthalmol 1993;115:608-613.
10. Takahashi K, Lam TT, Edward DP, et al. Protective effects of flunarizine on ischemic injury in the rat retina. Arch Ophthalmol 1992;110:862-870.
11. Saito S, Ohashi M, Naito A, et al. Neuroprotective effect of the novel Na+/Ca2+ channel blocker NS-7 on rat retinal ganglion cells. Jpn J Ophthalmol 2005;49:371-376.
12. Ishii K, Fukaya Y, Araie M, et al. Topical administration of iganidipine, a new water-soluble Ca2+ antagonist, increases ipsilateral optic nerve head circulation in rabbits and cynomolgus monkeys. Curr Eye Res 2004;29:67-73.
13. Maltese A, Bucolo C. Pharmacokinetic profile of topical flunarizine in rabbit eye and plasma. J Ocul Pharmacol Ther 2003;19:171-179.
14. Campana G, Bucolo C, Murari G, et al. Ocular hypotensive action of topical flunarizine in the rabbit: role of sigma 1 recognition sites. J Pharmacol Exp Ther 2002;303:1086-1094.
15. Beatty JF, Krupin T, Nichols PF, et al. Elevation of intraocular pressure by calcium channel blockers. Arch Ophthalmol 1984; 102:1072-1076.
16. Melena J, Santafe J, Segarra J. The effect of topical diltiazem on the intraocular pressure in betamethasone-induced ocular hypertensive rabbits. J Pharmacol Exp Ther 1998;284:278-282.
17. Osborne NN, Wood JP, Cupido A, et al. Topical flunarizine reduces IOP and protects the retina against ischemia-excitotoxicity. Invest Ophthalmol Vis Sci 2002;43:1456-1464.
18. Segarra J, Santafe J, Garrido M, et al. The topical application of verapamil and nifedipine lowers intraocular pressure in conscious rabbits. Gen Pharmacol 1993;24:1163-1171.
19. Tamaki Y, Araie M, Fukaya Y, et al. Effects of lomerizine, a calcium channel antagonist, on retinal and optic nerve head circulation in rabbits and humans. Invest Ophthalmol Vis Sci 2003;44:4864-4871.
20. Tamaki Y, Araie M, Tomita K, et al. Time change of nicardipine effect on choroidal circulation in rabbit eyes. Curr Eye Res 1996; 15:543-548.
21. Harino S, Riva CE, Petrig BL. Intravenous nicardipine in cats increases optic nerve head but not retinal blood flow. Invest Ophthalmol Vis Sci 1992;33:2885-2890.
22. Källberg ME, Brooks DE, Komaromy AM, et al. The effect of an L-type calcium channel blocker on the hemodynamics of orbital arteries in dogs. Vet Ophthalmol 2003;6:141-146.
23. Siegner SW, Netland PA, Schroeder A, et al. Effect of calcium channel blockers alone and in combination with antiglaucoma medications on intraocular pressure in the primate eye. J Glaucoma 2000; 9:334-339.
24. Netland PA, Grosskreutz CL, Feke GT, et al. Color Doppler ultrasound analysis of ocular circulation after topical calcium channel blocker. Am J Ophthalmol 1995;119:694-700.
25. Osborne NN, Ugarte M, Chao M, et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol 1999;43(suppl 1):S102-S128.
26. Cellini M, Possati GL, Caramazza N, et al. The use of flunarizine in the management of low-tension glaucoma: a color Doppler study. Acta Ophthalmol Scand Suppl 1997;224:57-58.
27. Munger RJ. Veterinary ophthalmology in laboratory animal studies. Vet Ophthalmol 2002;5:167-175.
28. Knollinger AM, La Croix NC, Barrett PM, et al. Evaluation of a rebound tonometer for measuring intraocular pressure in dogs and horses. J Am Vet Med Assoc 2005;227:244-248.
29. Leiva M, Naranjo C, Pena MT. Comparison of the rebound tonometer (ICare) to the applanation tonometer (Tonopen XL) in normotensive dogs. Vet Ophthalmol 2006;9:17-21.
30. Gelatt KN, Gum GG, Barrie KP, et al. Diurnal variations in intraocular pressure in normotensive and glaucomatous Beagles. J Glaucoma 1981;3:121-124.
31. Wilkie DA, Latimer CA. Effects of topical administration of timolol maleate on intraocular pressure and pupil size in dogs. Am J Vet Res 1991;52:432-435.
32. Skorobohach BJ, Ward DA, Hendrix DV. Effects of oral administration of methazolamide on intraocular pressure and aqueous humor flow rate in clinically normal dogs. Am J Vet Res 2003;64:183-187.
33. Abelson MB, Gilbert CM, Smith LM. Sustained reduction of intraocular pressure in humans with the calcium channel blocker verapamil. Am J Ophthalmol 1988;105:155-159.
34. Colasanti BK, Brown RE, Craig CR. Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol. Gen Pharmacol 1984; 15:479-484.
35. Gelatt KN, MacKay EO. Effect of different dose schedules of latanoprost on intraocular pressure and pupil size in the glaucomatous Beagle. Vet Ophthalmol 2001;4:283-288.
36. Gelatt KN, Mackay EO, Gelatt JK, et al. Effects on intraocular pressure and pupil size in glaucomatous beagles after topical pilocarpine instilled with standard (pH 5) and buffer-tip (pH 7) droptainers. J Ocul Pharmacol Ther 1997;13:95-104.
37. Holmes B, Brogden RN, Heel RC, et al. Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984;27:6-44.
38. + channels involved in neuronal cell death. Protection by flunarizine. Life Sci 1991;48:1881-1893.
39. Weizman R, Getslev V, Pankova IA, et al. Pharmacological interaction of the calcium channel blockers verapamil and flunarizine with the opioid system. Brain Res 1999:818:187-195.
40. Mito T, Delamere NA, Coca-Prados M. Calcium-dependent regulation of cation transport in cultured human nonpigmented ciliary epithelial cells. Am J Physiol 1993;264: C519-C526.
41. Lepple-Wienhues A, Rauch R, Clark AF, et al. Electrophysiological properties of cultured human trabecular meshwork cells. Exp Eye Res 1994;59:305-311.
42. Lepple-Wienhues A, Stahl F, Wiederholt M. Differential smooth muscle-like contractile properties of trabecular meshwork and ciliary muscle. Exp Eye Res 1991;53:33-38.
43. Erickson KA, Schroeder A, Netland PA. Verapamil increases outflow facility in the human eye. Exp Eye Res 1995;61:565-567.